Literature DB >> 16886615

Preliminary study of chemosenstivity tests in osteosarcoma using a histoculture drug response assay.

Soo Yong Lee1, Dae Geun Jeon, Wan Hyung Cho, Won Seok Song, Moon Bo Kim, Jong Hoon Park.   

Abstract

BACKGROUND: The clinical efficacy of chemotherapy is strongly correlated with the histoculture drug response assay (HDRA) in various types of cancers. However, there have been no previous reports on its use in osteosarcoma.
MATERIALS AND METHODS: Thirty-six fresh samples of human osteosarcoma were evaluated by the HDRA method in order to determine its possible usefulness in the treatment of this cancer. All the materials were obtained either during biopsy or surgical excision at our hospital, between January 2003 and October 2005.
RESULTS: A significant inhibition rate in primary biopsies was observed with Adriamycin (ADM) (47.3+/-15.3%); Cisplatin (CDDP) (36.3+/-22.3%); and Carboplatin (CBP) (50.5+/-23.3%); treatment. ADM and CBP demonstrated a statistically significant increase in inhibition rates compared to the other drugs.
CONCLUSION: Even though the HDRA method has many limitations, it might be a feasible and useful technique for selecting and predicting the efficacy of anticancer drugs for osteosarcoma patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16886615

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Activation of Cyclic Adenosine Monophosphate Pathway Increases the Sensitivity of Cancer Cells to the Oncolytic Virus M1.

Authors:  Kai Li; Haipeng Zhang; Jianguang Qiu; Yuan Lin; Jiankai Liang; Xiao Xiao; Liwu Fu; Fang Wang; Jing Cai; Yaqian Tan; Wenbo Zhu; Wei Yin; Bingzheng Lu; Fan Xing; Lipeng Tang; Min Yan; Jialuo Mai; Yuan Li; Wenli Chen; Pengxin Qiu; Xingwen Su; Guangping Gao; Phillip W L Tai; Jun Hu; Guangmei Yan
Journal:  Mol Ther       Date:  2015-09-16       Impact factor: 11.454

2.  Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics.

Authors:  Jing Cai; Yuan Lin; Haipeng Zhang; Jiankai Liang; Yaqian Tan; Webster K Cavenee; Guangmei Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-12       Impact factor: 11.205

3.  Proximal tumor location and fluid-fluid levels on MRI predict resistance to chemotherapy in stage IIB osteosarcoma.

Authors:  Dae-Geun Jeon; Won Seok Song; Wan Hyeong Cho; Chang-Bae Kong; Sang Hyun Cho
Journal:  Clin Orthop Relat Res       Date:  2014-02-27       Impact factor: 4.176

4.  Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers.

Authors:  Yuan Lin; Haipeng Zhang; Jiankai Liang; Kai Li; Wenbo Zhu; Liwu Fu; Fang Wang; Xiaoke Zheng; Huijuan Shi; Sihan Wu; Xiao Xiao; Lijun Chen; Lipeng Tang; Min Yan; Xiaoxiao Yang; Yaqian Tan; Pengxin Qiu; Yijun Huang; Wei Yin; Xinwen Su; Haiyan Hu; Jun Hu; Guangmei Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-06       Impact factor: 11.205

5.  Inhibition of the mevalonate pathway enhances cancer cell oncolysis mediated by M1 virus.

Authors:  Jiankai Liang; Li Guo; Kai Li; Xiao Xiao; Wenbo Zhu; Xiaoke Zheng; Jun Hu; Haipeng Zhang; Jing Cai; Yaya Yu; Yaqian Tan; Chuntao Li; Xincheng Liu; Cheng Hu; Ying Liu; Pengxin Qiu; Xingwen Su; Songmin He; Yuan Lin; Guangmei Yan
Journal:  Nat Commun       Date:  2018-04-18       Impact factor: 14.919

6.  Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines.

Authors:  Yanzhen Lin; Wei Wang; Junkai Wan; Ying Yang; Wenkun Fu; Dequan Pan; Linli Cai; Tong Cheng; Xiumin Huang; Yifeng Wang
Journal:  Virol J       Date:  2018-04-10       Impact factor: 4.099

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.